— Know what they know.
Not Investment Advice

PLSE NASDAQ

Pulse Biosciences, Inc.
1W: -5.7% 1M: +4.6% 3M: +19.3% YTD: +90.9% 1Y: +49.7% 3Y: +222.7% 5Y: +46.5%
$26.17
+0.61 (+2.40%)
 
Weekly Expected Move ±15.9%
$17 $21 $25 $28 $32
NASDAQ · Healthcare · Medical - Instruments & Supplies · Alpha Radar Strong Buy · Power 66 · $1.8B mcap · 13M float · 2.43% daily turnover · Short 49% of daily vol
Smart Money Score
Bullish 75
Insider+$26.6M
Congress
ETF Holdings
Key Statistics
Market Cap$1.8B
52W Range12.56-27.98
Volume290,086
Avg Volume310,009
Beta1.63
Dividend
Analyst Ratings
2 Buy 2 Hold 0 Sell
Consensus Buy
Company Info
CEOPaul Arthur LaViolette
Employees75
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date2016-05-18
3957 Point Eden Way
Miami, CA 94545
US
510 906 4600
About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Recent Insider Trades

NameTypeSharesPriceDate
DUGGAN ROBERT W P-Purchase 660,233 $19.69 2026-05-11
LAVIOLETTE PAUL A P-Purchase 15,000 $19.69 2026-05-11
LAVIOLETTE PAUL A P-Purchase 15,000 $19.69 2026-05-11
DUGGAN ROBERT W P-Purchase 660,233 $19.69 2026-05-11
UECKER DARRIN A-Award 100,000 2026-03-23

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms